Is therapeutic plasma exchange a better treatment than intravenous immunoglobulin in people with severe Guillain-Barre Syndrome (GBS)?

Not Applicable

Recruiting

• Conditions: Guillain-Barre Syndrome (GBS); Neurological - Other neurological disorders

• Registration Number: ACTRN12621000815864
• Lead Sponsor: Waikato Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-06-28
• Last Update Posted: 9 August 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

1)A diagnosis of GBS by Cornblath and Asbury criteria .
2)GBS severity of 4 or 5 by Hughes GBS severity scale OR early treatment outcome (EGOS) score of 5 or greater OR early GBS respiratory insufficiency (EGRIS) score of 5 or greater.
3)Able to start assigned treatment within 2 weeks of weakness onset.
4)At least 18 years of age at the time of enrollment.
5)Able to provide informed consent

Exclusion Criteria

1) Any antecedent illness that would interfere with the ability to perform outcome assessments
2)History of an allergy to IVIg
3)History of an allergic reaction to Albumin 4%.
4)History of IgA deficiency with anti-IgA antibodies
5)Known reaction to blood products
6)Patient with strong objection to the use of blood products

Study & Design

• Study Type: Interventional
• Study Design: Not specified